More Cycles of Decitabine Equals Better MDS Outcomes

TON - October 2010, Vol. 3, No 7 published on October 22, 2010 in Rare Cancers

CHICAGO—Patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMAs), especially decitabine, are more likely to achieve hematologic responses when treated with a greater number of cycles, investigators from Georgia Cancer Specialists in Marietta reported at the 2010 annual meeting of the American Society of Clinical Oncology.

“The likelihood of improvement in anemia, thrombocytopenia, and neutropenia is associated with the number of cycles. For every extra cycle, the chance of improvement increases,” said Rodolfo Bordoni, MD. Responses increased by 15% to 19% with each additional cycle beyond the first.

Although clinical trials of HMAs have demonstrated a range of clinical benefits, concern exists about the applicability of trial results in the community practice setting where patients may differ in terms of demographics, risk level, comorbidities, and treatment regimen, Bordoni noted.

“We therefore examined hematologic outcomes in MDS among patients treated with the HMAs azacitidine and decitabine in a large community hematology/oncology practice,” he said.

This was a retrospective observational study of patients through electronic medical record data for 2006-2009. The population included 1070 patients with intermediate- or high-grade MDS, 137 (13%) of whom received azacitidine (n = 53) or decitabine (n = 84). The groups were well-balanced except that decitabine recipients were somewhat sicker, he noted.

The Charlson comorbidity index was ≥1 in the month preindex for 40/53 on azacitidine and 66/84 on decitabine. Mean Charlson index was 1.2 for the azacitidine group and 1.7 for the decitabine group. Mean number of cycles was five for azacitidine and four for decitabine.

Response increased per cycle
The total number of cycles significantly predicted hemoglobin level (odds ratio [OR], 1.19; P = .029), platelet count (OR, 1.15; P = .031), and absolute neutrophil count (ANC) (OR, 1.16; P = .047), Bordoni reported.

This improvement, however, was largely driven by decitabine, which was associated with a 58% improvement in hemoglobin response per additional cycle (P = .0035). There was also a trend toward a greater likelihood of hemoglobin ≥11 g/dL for decitabine over azacitidine (OR, 2.70; P = .085) after controlling for the number of cycles given. Although decitabine decitabinetreated patients were also more likely to have a platelet response, the difference was not statistically significant after controlling for the number of cycles.

The drugs were equally likely to produce an ANC response. The use of growth factors during treatment was negatively associated with ANC response (OR, 0.96; P = .046) as well as hemoglobin response (OR, 0.85; P = .007), he added.

The findings suggest that “we should not give up on slow responders,” Bordoni said. “Continuing on treatment is the key to hematologic response.”

Related Items
Duloxetine Improves Chemotherapy-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer
Wayne Kuznar
TON - March 2017, Vol 10, No 2 published on March 7, 2017 in Rare Cancers
July Is Sarcoma Awareness Month
E. K. Charles, MBS
TON July 2016 Vol 9 No 4 published on July 18, 2016 in Rare Cancers
Promising Vaccine Combination Identified for Patients With Metastatic Pancreatic Cancer
Wayne Kuznar
TOP - May 2014, Vol 7, No 2 published on June 10, 2014 in Rare Cancers
Sorafenib Effective in Metastatic Differentiated Thyroid Cancer
Audrey Andrews
TON - August 2013 Vol 6 No 7 published on September 4, 2013 in Rare Cancers
Advances in the Treatment of Pancreatic Neuroendocrine Tumors
Caroline Helwick
TOP - December 2012 VOL 5, NO 8 published on December 20, 2012 in Rare Cancers
Advances in the Treatment of Pancreatic Neuroendocrine Tumors
Caroline Helwick
TON - November 2012, Vol 5, No 10 published on November 21, 2012 in Rare Cancers
FOLFIRINOX in metastatic pancreatic adenocarcinoma
TOP - Daily published on August 30, 2011 in Rare Cancers
Pancreatic Neuroendocrine Cancer
Dori L. Klemanski, MS, MS, RN, CNP
TON - Other published on May 6, 2011 in Rare Cancers
Last modified: May 21, 2015